Q3 FY26 · Ended Sep 30, 2026 · View SEC filing
Most of the margin jump is missing deal charges
Lower charges for bought-in programs explain two thirds of the margin gain, so a single large license could reverse much of it.
For investorsWhat the margin depends on once the deals return
For foundersBuying what others de-risked: the staged licensing playbook
Non-cash charges from past acquisitions hold net income down; the dividend, the debt and new deals run on the cash.
The filing ties last year's high tax rate to deals and earn-outs, so net earnings swung far more than operating earnings.
Skyrizi and Rinvoq more than covered Humira's biosimilar losses, and they sell to the prescribers and payers Humira already served.
Unlock the financial breakdown, competitive insights, historical trends and founder playbook, plus research across the company library.
Free CXProWealth membership required
Business Lens describes AbbVie from its own filings with the SEC. It is not a view on its shares, a target, or advice to buy, sell or hold anything; figures are as filed and may be restated by the company later. The filing is linked above.